CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 121 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Amisulpride 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02557984
NCT02557984N/ACompleted

Dopamine D2/3- and μ-opioid Receptor Antagonists Reduce Cue-induced Reward Responding and Reward Impulsivity in Healthy Volunteers

University of Zurich·interventional·Posted Sep 23, 2015·Updated Sep 23, 2015

In Brief

A clinical study evaluating Placebo, Amisulpride, and 1 other intervention for Addiction. Completed, enrolled 121 participants across 1 site.

Detailed Summary

The purpose of this study is to determine how the dopamine and opioid system is involved in reward processing, specifically in cue-induced reward responding and reward impulsivity, using dopamine and opioid receptor antagonists in healthy participants. The investigators predict that particularly the dopamine challenge should alter cue-induced reward responding and reward impulsivity. Such effects would be of high interest for the treatment of disorders which involve impairments of reward processing such as addiction.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAddiction
CountriesSwitzerland
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 23, 2015
Enrollment StartFeb 1, 2014
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 10.8 years ago

Interventions

Placebodrug

Placebo Pill

Amisulpridedrug

400 mg Amisulpride

Naltrexonedrug

50 mg Naltrexone